In-Vitro Diagnostic Substance Manufacturing (U.S.) — NAICS 325413

1. Overview

Almost every medical decision starts with a test. When a lab measures your blood sugar, screens a Pap smear for cervical cancer, confirms a strep throat, checks a heart-attack biomarker, or types blood before a transfusion, it consumes a reagent — a chemical or biological substance that reacts with a patient sample to produce a readable result. The companies in this industry make those substances: the reagents, test kits, calibrators, and controls used to run diagnostic tests on samples taken outside the body (in Latin, in vitro, "in glass"). [1]

"In-vitro diagnostics," or IVD (testing done on a blood, urine, tissue, or swab sample in a lab or at the bedside, as opposed to imaging or testing inside the body), is one of the most attractive corners of health care for an investor to understand, for one reason: it runs on a razor-and-blade model. A manufacturer places an analyzer instrument in a hospital or reference lab — often cheaply — and then sells the proprietary reagents that the machine consumes, test after test, for years. The instrument is the razor; the reagents are the blades. That produces recurring, high-margin, recession-resistant revenue. Under reagent-rental contracts, the supplier retains title to the analyzer and recovers its cost through multi-year minimum purchases of assays and reagents. [2]

Why an investor cares: diagnostics guide an estimated majority of clinical decisions while costing a small slice of total health spending, demand grows with an aging, chronically ill population, and the reagent stream is sticky. Note a scope point that matters for this specific code: NAICS 325413 covers the diagnostic substances (the blades), not the analyzers (the razors) — instruments sit in a separate manufacturing code. So the federal statistics below measure U.S. reagent and test-kit production, a piece of the larger IVD system, not the whole thing.

• Public-market route: Diagnostics is dominated by large, diversified, listed companies — Abbott, Danaher, Thermo Fisher, Roche, Siemens Healthineers, bioMérieux, and mid-caps such as QuidelOrtho, Hologic, Bio-Rad, and Qiagen. There is no clean pure-play "reagent" stock; you buy a segment inside a bigger firm. [3][4]
• Private route: Venture and growth capital fund early-stage assay and molecular-test developers; private equity has owned and traded reagent platforms (Ortho Clinical Diagnostics was PE-owned before its 2022 merger); and several sizeable players are private or foreign-family-controlled (Werfen, Sekisui Diagnostics, Sysmex). [5]

(NAICS = North American Industry Classification System, the U.S. government's standard scheme for grouping businesses.)

2. What it is and how it's structured

In scope (NAICS 325413): Establishments primarily manufacturing in-vitro diagnostic substances — chemical, biological, or radioactive — used to run diagnostic tests in test tubes, on analyzers, and on test-type devices. That includes blood-glucose test strips and kits; pregnancy and hormone test kits; reagents for clinical chemistry, hematology, microbiology, virology, cytology, and immunology; and infectious-disease kits such as HIV and other viral tests. [1]

What it explicitly excludes — this is where the code's boundaries matter:

• In-vivo diagnostic substances (contrast agents and tracers used inside the body, e.g., for imaging) → NAICS 325412, In-Vivo Diagnostic Substance Manufacturing. [1]
• Vaccines, toxoids, blood fractions, and non-diagnostic culture media → NAICS 325414, Biological Product (except Diagnostic) Manufacturing. [1]
• The analyzers and instrument systems themselves (the machines that read the reagents) → NAICS 334516, Analytical Laboratory Instrument Manufacturing. [1]
• The clinical labs that run the tests (hospital labs, LabCorp, Quest) → medical/diagnostic laboratory services codes, not manufacturing.

That last point is the crux: a single IVD business — say, a Roche or an Abbott — spans several of these codes. Its analyzer revenue lands in the instrument code, its lab-service partnerships elsewhere, and only the reagent/kit manufacturing shows up in 325413. Treat this code as the consumables engine of the diagnostics economy, not the full economy.

Manufacturing process: The process varies by assay but generally involves producing or sourcing antibodies, antigens, enzymes, nucleic-acid primers and probes, cell lines, serum-derived controls, chemical substrates, and calibrators; formulating these to validated concentrations; filtration or purification; coating or filling slides, cards, strips, cartridges, wells, or reagent packs; lyophilization where needed; and packaging under controlled conditions. Lot-release testing, stability studies, traceability, contamination control, labeling, and cold-chain logistics are economically important because an apparently small change in raw material or process can alter sensitivity, specificity, or calibration. QuidelOrtho's U.S. operations, for example, include cell culture, bacterial fermentation, protein purification, antibody and reagent filling, lyophilization, microbially controlled filling, chemistry and serological testing, slide coating, and cold-chain warehousing — specialized batch manufacturing combined with high-volume automation, not ordinary commodity chemical blending. [6]

Ownership mix: The industry is dominated by large, publicly traded, multinational manufacturers, plus their U.S. subsidiaries. It is not a fragmented, mom-and-pop industry — but its establishment base is more varied than the household-name giants suggest, because there is a long tail of specialty reagent, antibody, and niche-assay makers supplying the majors and academic labs (see the concentration numbers in Section 3).

3. How big it is (federal figures)

Our ground-truth U.S. federal statistics for NAICS 325413:

Concentration (2022 Economic Census): the top 4 firms account for 48.8% of industry revenue, the top 8 for 65.6%, the top 20 for 86.2%, and the top 50 for 96.1%. The Herfindahl-Hirschman Index (HHI, a standard concentration gauge that runs from near 0 for perfect competition to 10,000 for a monopoly) is 752.2. [7]

Read those two facts together: the top handful of firms make roughly half of everything, yet the HHI of 752 sits below the U.S. antitrust threshold for a "concentrated" market (1,500). Reconciled honestly, that means a few giants lead each testing category, but no one firm dominates the whole industry, and dozens of smaller specialty reagent makers fill out the tail. High wages (~$115k average) reflect a scientist- and engineer-heavy workforce.

The undercount / miscount caveat — important here. The $23.1 billion figure is U.S. domestic reagent-and-substance production, and it should not be confused with either the U.S. IVD market or the diagnostics revenue of the big companies:

• It excludes analyzers/instruments (NAICS 334516) and lab-testing services, so it captures only part of the value chain. Third-party analysts put the broader U.S. in-vitro diagnostics market at roughly $35 billion in 2024, of which reagents are about two-thirds — a different, larger boundary than this code. [3]
• It counts what is made in U.S. establishments, so it understates the reagents Americans use that are imported (from Roche/Germany-Switzerland, Siemens Healthineers/Germany, bioMérieux/France, and Chinese suppliers), and it does not capture the overseas production and sales of U.S.-headquartered firms like Abbott, Danaher, and Thermo Fisher. Company revenue figures in Section 4 are global and are therefore many times larger than this domestic-production number. This is a boundary difference, not an error in either figure.

4. The investable universe

There is no listed "pure-play reagent manufacturer." Diagnostics is owned inside diversified health-care and life-science companies, where IVD is one reporting segment. Public plays (scale = most recent reported diagnostics-related revenue, which spans reagents and instruments globally):

Concentration for investors: worldwide, the top ~13 IVD companies reported roughly $91.9 billion of diagnostic-related revenue in 2024, up from $88.7 billion in 2023, with Roche, Abbott, Danaher, and Thermo Fisher at the top. In the U.S. market specifically, Abbott has historically held about 20% share and Danaher about 11%. Bio-Rad identifies Abbott, Becton Dickinson, bioMérieux, Danaher, DiaSorin, Werfen, QuidelOrtho, Roche, Siemens Healthineers, Thermo Fisher Scientific, and Tosoh as major Clinical Diagnostics competitors. [4][17][19]

Major private / other owners: Ortho Clinical Diagnostics was owned by private-equity firm Carlyle before merging with Quidel in 2022. Still-private or family/foreign-controlled players include Werfen (Spain; hemostasis and autoimmunity), Sekisui Diagnostics (subsidiary of Japan's Sekisui Chemical), Sysmex (Japan; hematology, TSE-listed), DiaSorin (Italy; immunodiagnostics), and Grifols (Spain; transfusion/immunoassay). China's Mindray and BGI are large and growing. Early-stage assay and molecular-test developers are the main venture-capital hunting ground.

5. How the money works

Owners in this industry make money on consumables, not machines. The economics that matter:

• Installed base × pull-through. The key operating metric is not a single sale but the installed base (number of a manufacturer's analyzers placed in labs) multiplied by reagent pull-through (annual reagent revenue per instrument). Hologic, for example, grew its molecular Panther installed base from roughly 1,700 instruments in 2019 to more than 3,330 by fiscal 2024 — each one a multi-year annuity of test-kit sales. [15]
• Closed systems and switching costs. Analyzers run only the maker's proprietary reagents, and lab contracts typically run 5–7 years. Once a lab validates a platform (a regulated, labor-intensive process), switching is expensive and slow. That lock-in is the moat. [2]
• Recurring-revenue ratio and margins. Because every test burns a dedicated reagent, mature IVD franchises carry very high recurring-revenue shares — Danaher reported that recurring products represented 89% of its Diagnostics segment's 2025 sales, showing how economically different an installed platform is from a one-time instrument sale. This underpins fat gross margins and steady cash flow. [2][10]
• Menu breadth. Profitability rises with the number of tests ("menu") a platform can run, because it spreads the fixed cost of an instrument placement across more reagent pulls and makes the system more valuable to a lab.
• Instrument-placement economics. The model is not costless. Reagent rental consumes cash upfront because the manufacturer funds the instrument and recovers its investment over the contract. QuidelOrtho transferred $167.3 million of instrument inventory to property, plant and equipment during 2025 as it expanded instrument placements. The economics depend on winning sufficient test volume, enforcing minimum purchases, and retaining the account long enough to recover the analyzer and service cost. [6]
• Volume and reimbursement. Revenue ultimately tracks test volume (procedures run) times price per test, and price is heavily influenced by what payers reimburse (Section 7). A reagent maker wins by getting on high-volume, high-menu platforms and keeping them full.

The upshot: this is a capital-light-once-placed, annuity-like business. The risk is front-loaded (winning the placement, clearing regulators); the reward is a long tail of reagent margin. It is far closer to a subscription/consumables model than to episodic capital-equipment manufacturing.

Input costs: Principal costs include antibodies, antigens, enzymes, serum and other biological material; specialty chemicals; plastics and packaging; electronics and optics embedded in cartridges or systems; manufacturing and quality labor; depreciation; clinical validation; regulatory affairs; field service; and temperature-controlled distribution. Bio-Rad reports using chemicals, biological materials, electronic components, machined metal and optical parts, and computing devices, with some sole-source inputs — and notes that higher raw-material costs are not always recoverable from customers. [17]

6. What drives demand

• Aging population and chronic disease. Older patients generate a disproportionate share of routine chemistry and immunoassay testing; diabetes, cardiovascular disease, and chronic kidney disease drive enormous recurring test volumes. This is the structural, non-cyclical demand base. [20]
• Infectious disease and outbreaks. Respiratory panels (flu, RSV, COVID-19), sexually transmitted infections, and hospital-acquired infections drive molecular and rapid-test demand — and can spike sharply during outbreaks (the COVID-19 surge, and its subsequent collapse, is the clearest recent example). [20]
• The shift to molecular and point-of-care. Molecular diagnostics (tests that read DNA/RNA — PCR, next-generation sequencing) is the fastest-growing category, and point-of-care testing (POC, run at the bedside, pharmacy, or home rather than a central lab) is expanding decentralized testing. Analysts project the global point-of-care segment growing at roughly 9% a year into the early 2030s — a forward-looking estimate, not a reported figure. [20][21]
• Precision medicine and companion diagnostics. Cancer therapies increasingly require a companion test to identify eligible patients, tying reagent demand to the drug-development pipeline.
• Preventive and wellness testing. Wider screening, at-home testing, and consumer health monitoring broaden the base of tests run per person.
• Central-lab automation. Central laboratories are adopting higher-throughput automation and informatics to compensate for staffing constraints, which can increase instrument utilization and reagent pull-through.

Countervailing trend — buyer consolidation. Hospital systems, national reference laboratories, group-purchasing organizations, and government tenders can aggregate volume and demand lower prices. China's volume-based procurement programs have already pressured multinational diagnostics vendors; Abbott attributed weaker Chinese Core Laboratory performance partly to those programs. [11]

7. Regulation

IVDs are regulated at two layers, and both drive real cost and competitive advantage:

• FDA product clearance. The U.S. Food and Drug Administration (FDA) regulates diagnostic reagents/kits as medical devices, via three main pathways of rising rigor: 510(k) (show "substantial equivalence" to an existing legally marketed predicate device — the common route), De Novo (for novel moderate-risk tests with no predicate), and PMA (Premarket Approval — the most demanding route, for high-risk Class III tests). Some blood-screening products can involve biologics regulation. [22]
• CLIA lab categorization. The Clinical Laboratory Improvement Amendments (CLIA) framework categorizes each test by complexity — waived, moderate, or high complexity. A CLIA-waived test can be run outside a sophisticated lab (a pharmacy, clinic, or home), which dramatically widens its market; getting a waiver (often via a combined "dual 510(k) and CLIA waiver" submission) is a major commercial lever. [22]
• Quality Management System Regulation (QMSR). FDA's QMSR became effective on February 2, 2026 and incorporates ISO 13485:2016 into the U.S. device-quality framework. FDA can now inspect records such as management reviews, quality audits, and supplier audits that previously received different treatment under the old inspection system. [23]
• Reimbursement (CMS/payers). What Medicare pays sets the price ceiling for much of the market. The Centers for Medicare & Medicaid Services (CMS) pays for lab tests under the Clinical Laboratory Fee Schedule (CLFS), and under the Protecting Access to Medicare Act (PAMA) those rates are pegged to the median of private-payer rates and updated periodically. CMS states that private-payor data will reset CLFS amounts for 2027 and that payment reductions may be as much as 15% per year through 2029. Reagent makers are indirectly exposed because their lab customers' economics ride on these rates. [24]

The LDT saga (a live regulatory swing). Laboratory-developed tests (LDTs, tests designed and run in-house by a single lab rather than sold as kits) have historically escaped FDA device review. In May 2024 the FDA issued a final rule to regulate LDTs as devices; in March 2025 a federal court in Texas vacated that rule, holding the FDA lacked statutory authority; and in September 2025 the FDA formally rescinded it. The net effect: for now, kit manufacturers (this industry) remain fully FDA-regulated, while their lab-based competitors running LDTs do not — a competitive asymmetry worth watching. [25]

8. Competitive dynamics and consolidation

• Scale is the game. Winners own large installed bases, broad test menus, and global distribution. That favors the majors and drives relentless consolidation — buying reagent menus, molecular platforms, and installed bases rather than building them slowly.
• Landmark deals. Danaher assembled its diagnostics arm by acquiring Beckman Coulter (2011) and molecular leader Cepheid (2016). QuidelOrtho was created in May 2022 when Quidel bought Ortho Clinical Diagnostics for roughly $6 billion of equity value, combining rapid/point-of-care with clinical-chemistry and transfusion menus. Most recently, Becton Dickinson agreed in 2025 to spin off and merge its Biosciences and Diagnostic Solutions business into Waters in a ~$17.5 billion Reverse Morris Trust deal that closed in February 2026 — reshuffling a large diagnostics portfolio into a new combined company. [5][10][18]
• Barriers to entry are high. Regulatory clearance, the installed-base flywheel, long lab contracts, and menu breadth make it very hard for a startup to displace an incumbent on a routine, high-volume test. New entrants usually win by (a) inventing a genuinely new category (novel molecular or multi-cancer-detection assays), then (b) getting acquired.
• Where competition is fiercest: newer, higher-growth niches — molecular/NGS, companion diagnostics, point-of-care, and at-home testing — where installed bases are still being contested. Routine chemistry and immunoassay are more entrenched.

9. Risks

• Post-COVID normalization. The pandemic inflated respiratory and COVID-19 test revenue, and its unwind has cut sales at COVID-exposed names. Abbott's COVID-related rapid-test sales fell from $725 million in 2024 to $285 million in 2025, while its non-COVID Core Laboratory business continued growing; QuidelOrtho likewise reported declining point-of-care revenue as SARS antigen sales normalized. Comparisons and mix are still normalizing. [6][11]
• Reimbursement pressure. PAMA-driven CLFS cuts squeeze the lab customers who buy reagents; CMS indicates payment reductions of up to 15% per year may apply through 2029. Broader payer cost-containment caps test prices. [24]
• Tariffs and supply chain. Reagents, plastics, and instrument components move globally. New U.S. tariffs on Chinese (and some Canadian/Mexican) medical imports in 2025 — ranging from ~10% to well over 100% on certain goods — plus persistent sourcing difficulty for critical reagents and labware, raise input costs and complicate supply. QuidelOrtho reports dependence on single- and sole-source suppliers, shortages, long ordering lead times, logistics problems and rising labor costs; regulatory requirements can prevent rapid supplier substitution. [6][26]
• Regulatory whiplash. The LDT rule's issuance, vacatur, and rescission in barely 18 months shows how quickly the competitive playing field between kit makers and in-house labs can shift. [25]
• Concentration and customer power. Large reference labs and hospital purchasing groups have real negotiating leverage over reagent pricing. China's volume-based procurement programs have already pressured multinational diagnostics vendors. [11]
• Technology disruption. A superior new platform (e.g., a cheaper decentralized molecular system, or a blood-based multi-cancer screen) can strand an incumbent's installed base over time.
• FX exposure. Because the leaders are global, reported growth swings materially with the dollar's moves against the franc, euro, and yen. [9][12][13]

10. How to invest and the outlook

Public routes. The straightforward way in is the diversified leaders — Abbott (ABT), Danaher (DHR), Thermo Fisher (TMO), Roche (RHHBY), and Siemens Healthineers (SHL) — where diagnostics is a large, high-quality segment but not the whole company. For more concentrated diagnostics exposure, mid-caps like QuidelOrtho (QDEL), Hologic (HOLX), Bio-Rad (BIO), Qiagen (QGEN), and bioMérieux (BIM) tilt harder toward IVD, at the cost of more single-category and post-COVID-mix risk. Broad health-care and medical-device ETFs also capture the theme. (Valuation multiples, dividend yields, and share prices vary widely across these names and change constantly — size positions to the specific company's growth and margin profile, not to the sector label.)

Private routes. Venture and growth funds back early-stage assay, molecular-test, and at-home-diagnostics developers, where the realistic exit is acquisition by a major. Private equity has repeatedly owned and traded reagent platforms (Ortho under Carlyle is the template). And several substantial operators — Werfen, Sekisui Diagnostics, Sysmex, Grifols — are private or foreign-controlled and reachable only through direct/co-investment or their home-market listings. Private diligence should reconstruct revenue by assay and installed platform; separate regulated IVD from research-use-only products; examine customer and distributor concentration; quantify instrument-placement capital; review lot-failure, expiry and complaint history; and test whether gross margin survives realistic service, quality, regulatory, and replacement-instrument costs.

Near-term drivers (forward-looking). Watch: (1) molecular and point-of-care menu expansion — the fastest-growing, most contested ground; (2) installed-base and pull-through trends at the platform owners, the truest leading indicator of future reagent revenue; (3) reimbursement outcomes — the 2027 CLFS reset and potential 15% annual cuts through 2029; (4) M&A — expect continued portfolio reshuffling now that the BD–Waters combination has closed; and (5) tariff and supply-chain costs. The structural case is durable: an aging, chronically ill population running ever more tests, on sticky razor-and-blade platforms, is a slow-growing but resilient annuity. Independent analysts project the broader IVD market compounding in the mid-single digits over the coming decade — a projection, not a guarantee, and one that assumes reimbursement and trade conditions don't tighten sharply. [3][20]

---

Sources

1. NAICS Association / U.S. Census Bureau. "NAICS Code 325413 — In-Vitro Diagnostic Substance Manufacturing" (definition, inclusions, and exclusions to 325412, 325414, 334516). https://www.naics.com/naics-code-description/?code=325413
2. note.com (ZERO) / MedTech Terms. "Why Analytical Instrument Manufacturers Are Strong: the razor-and-blade model and recurring-revenue ratio" (2024). https://note.com/all_zero/n/nc9f7d8527852?hl=en; https://medtechterms.com/terms/razor-razorblade
3. Nova One Advisor / Precedence Research. "U.S. In Vitro Diagnostics Market Size" (~$34.98B in 2024; reagents ~66% of IVD) (2025). https://www.novaoneadvisor.com/report/in-vitro-diagnostics-ivd-market; https://www.precedenceresearch.com/us-in-vitro-diagnostics-market
4. The Dark Report (Dark Intelligence Group). "2025 Ranking of the World's Top 13 IVD Corporations" (top-13 diagnostic revenue $91.9B in 2024) (2025). https://www.darkintelligencegroup.com/the-dark-report/in-vitro-diagnostics/2025-ranking-of-the-worlds-top-13-ivd-corporations/
5. AACC/ADLM and QuidelOrtho. "Quidel Corporation Buys Ortho Clinical Diagnostics" (2022 merger, ~$6B equity value; Ortho formerly Carlyle-owned). https://myadlm.org/cln/articles/2022/march/quidel-corporation-buys-ortho-clinical-diagnostics; https://www.quidelortho.com
6. QuidelOrtho Corporation. Form 10-K FY2025 (manufacturing operations, instrument placements, $167.3M inventory transfer, supply-chain risks). U.S. SEC. https://www.sec.gov/Archives/edgar/data/1906324/000190632426000008/qdel-20251228.htm
7. U.S. Census Bureau, 2022 Economic Census — Concentration ratios, NAICS 325413 (receipts $23,121,300 thousand; 207 firms; CR4 48.8%, CR8 65.6%, CR20 86.2%, CR50 96.1%; HHI 752.2). (Ground-truth federal data.)
8. U.S. Census Bureau, County Business Patterns 2023 — NAICS 325413 (267 establishments; 45,459 employees; annual payroll $5,246,163 thousand). (Ground-truth federal data.)
9. 360Dx. "Roche Diagnostics 2024 Revenues Down 1 Percent" (CHF 14.32B diagnostics division) (2025). https://www.360dx.com/business-news/roche-diagnostics-2024-revenues-down-1-percent
10. Danaher Corporation. 2025 Annual Report (Diagnostics segment $9.941B; 89% recurring products; owns Cepheid, Beckman Coulter, Leica, Radiometer). U.S. SEC. https://www.sec.gov/Archives/edgar/data/313616/000031361626000105/danaher2025annualreport.htm
11. Abbott Laboratories. Form 10-K FY2025 (Diagnostics segment $8.937B; COVID rapid-test decline $725M→$285M; China volume-based procurement impact). U.S. SEC. https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm
12. Siemens Healthineers. "Fiscal Year 2024 results" (Diagnostics segment €4,417M) (2024). https://www.siemens-healthineers.com/press/releases/2024q4
13. bioMérieux. "2024 Financial Results" (consolidated sales €3,980M) (2025). https://www.biomerieux.com/corp/en/journalists/press-releases/2024-full-year-financial-results.html
14. Thermo Fisher Scientific. "Fourth Quarter and Full Year 2024 Results" ($42.88B total revenue; Specialty Diagnostics ~10%) (2025). https://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientific-Reports-Fourth-Quarter-and-Full-Year-2024-Results/
15. Hologic, Inc. "Financial Results for Fourth Quarter of Fiscal 2024" (Diagnostics revenue $1.78B; Panther installed base >3,330) (2024). https://www.hologic.com/about/press-release/hologic-announces-financial-results-fourth-quarter-fiscal-2024
16. Qiagen N.V., Form 20-F FY2024 (total revenue $1.978B; molecular diagnostics growth). U.S. SEC. https://www.sec.gov/Archives/edgar/data/1015820/000101582025000027/qgen-20241231.htm
17. Bio-Rad Laboratories. Form 10-K FY2025 (Clinical Diagnostics segment $1.562B; competitor list; input costs and sole-source suppliers). U.S. SEC. https://www.sec.gov/Archives/edgar/data/12208/000001220826000010/bio-20251231.htm
18. Becton Dickinson / Waters Corporation. "BD to combine Biosciences and Diagnostic Solutions with Waters" (Reverse Morris Trust, ~$17.5B; ~$6.5B combined sales; closed Feb 9, 2026). U.S. SEC Form 8-K/425 (2025); BD Form 10-K FY2025. https://www.sec.gov/Archives/edgar/data/10795/000119312525158404/d41030dex991.htm
19. MarketsandMarkets. "Danaher and Roche Leading Players in the U.S. In Vitro Diagnostics Market" (Abbott ~20%, Danaher ~11% U.S. share). https://www.marketsandmarkets.com/ResearchInsight/u-s-in-vitro-diagnostics-companies.asp
20. Nova One Advisor / MarketsandMarkets. "In Vitro Diagnostics Market — demand drivers (aging, chronic disease, molecular, point-of-care)" (2025). https://www.novaoneadvisor.com/report/in-vitro-diagnostics-ivd-market
21. MarketsandMarkets. "Point of Care Diagnostics Market" (global POC ~$20.6B in 2026 to ~$31.5B by 2031, ~8.8% CAGR) (2025). https://www.marketsandmarkets.com/Market-Reports/point-of-care-diagnostic-market-106829185.html
22. U.S. Food and Drug Administration. "IVD Regulatory Assistance — 510(k), De Novo, PMA pathways; CLIA Categorizations and CLIA Waiver by Application" (waived/moderate/high complexity). https://www.fda.gov/medical-devices/ivd-regulatory-assistance/clia-categorizations; https://www.fda.gov/medical-devices/ivd-regulatory-assistance/clia-waiver-application
23. U.S. Food and Drug Administration. "Quality Management System Regulation (QMSR)" (effective Feb 2, 2026; incorporates ISO 13485:2016). https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
24. Centers for Medicare & Medicaid Services. "Clinical Laboratory Fee Schedule (CLFS) and PAMA reporting resources" (2027 reset; up to 15% annual cuts through 2029). https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule/clfs-pama-reporting-resources
25. Covington & Burling / FDA. "FDA's LDT Rule Struck Down" (May 2024 final rule; vacated by E.D. Texas March 31, 2025; FDA rescission Sept 2025). https://www.cov.com/en/news-and-insights/insights/2025/04/fdas-ldt-rule-struck-down-by-federal-district-court; https://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests
26. Sekisui Diagnostics / 360Dx. "What Supply Chain Disruptions and Tariffs Mean for Diagnostic Labs in 2025" (2025 U.S. tariffs on medical/lab imports, ~10% to >100%; reagent sourcing strain). https://blog.sekisuidiagnostics.com/dxdialogue/what-supply-chain-disruptions-and-tariffs-mean-for-diagnostic-labs-in-2025; https://www.360dx.com/business-news/chinese-procurement-policy-us-tariffs-stifling-diagnostic-companies-china